8
Oct
2024
AqVida GmbH
Exhibitor at CPHI Milan 2024 stand 14G1, Finished Dosage Formulations
About Us
Categories
-
DE -
2015On CPHI since
-
2Certificates
-
50 - 99Employees
Company types
Contact info
-
-
-
Kaiser-Wilhelm-Str. 89, D-20355 , Hamburg, Germany
Event information
CPHI Milan 2024
-
08 Oct 2024 - 10 Oct 2024
-
Fiera Milano, Italy
-
Visit us at stand 14G1, Finished Dosage Formulations
Products Featured at CPHI Milan 2024
-
Product Docetaxel AqVida 20 mg/ml concentrate for solution for infusion
20 mg, 80 mg, 140 mg, 160 mg vial Indications: Treatment of breast cancer, special form of lung cancer, prostate cancer, gastric cancer and head or neck cancer -
Product Epirubicin AqVida 2 mg/ml solution for injection
10 mg, 20 mg, 50 mg, 100 mg, 200 mg vialIndications: Treatment of breast cancer, advanced ovarian cancer, stomach cancer, small cell lung cancer, bladder cancer -
Product Gemcitabine AqVida 38 mg/ml powder for solution for infusion
200 mg, 1 g, 2 g vial Indications: Treatment of NSCLC, pancreatic cancer, bladder cancer, breast cancer -
Product Imatinib AqVida hard capsules*
100 mg, 200 mg, 400 mg capsuleIndications: Treatment of chronic myeloid leukaemia, GIST * Products protected by valid patents are not offered in countries where the sale constitutes a patent infringement. -
Product Irinotecan AqVida 20 mg/ml concentrate for solution for infusion
40 mg, 100 mg, 300 mg vial Indications: Treatment of advanced colorectal cancer
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance